Vital Signs buys fluid warming company:
This article was originally published in Clinica
Anaesthesia breathing systems manufacturer Vital Signs has bought blood warming technology specialist Enginivity in a deal worth $5.9m. The deal sees Totowa, New Jersey-based Vital Signs acquire the enFlow device, a fluid warming system that brings the warming element closer to the patient, reducing heat loss and post-operative infections. The enFlow device will be introduced to market in November, and provides the company with an entry into what it claims is a $40-45m domestic market. Enginivity (Lexington, Massachusetts) sold its FDA-cleared and CE-marked products to hospitals and the US government but received no revenue in 2006.
You may also be interested in...
FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.
Warning letters show FDA's coronavirus investigations inthe consumer health marketplace didn't stop when it suspended facility inspections. The letters identify firms that previously marketed only bedding products as offering supplements with coronavirus claims or that are in other countries and are shipping to US consumers products promoted with coronavirus claims.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.